Tuesday, August 21, 2018

PRO/AH/EDR> Ebola update (73): Congo DR (NK) cases, anti-viral, research

A ProMED-mail post
ProMED-mail is a program of the
International Society for Infectious Diseases

In this update:
[1] Case update
- Epidemiological situation report, 19 Aug 2018, DRC Ministry of
[2] Experimental anti-viral
- mAB114
[3] Research
- biorxiv

[1] Case update
- Mon 20 Aug 2018. Epidemiological situation report, 19 Aug 2018, DRC
Ministry of Health
[in French, machine trans., edited]

- A total of 96 cases of haemorrhagic fever were reported in the
region, 69 confirmed and 27 probable.
- 5 suspected cases are under investigation .
- 5 new confirmed cases in Mabalako.
- 5 confirmed case deaths in Mabalako

News of the response
Free care
The Ministry of Health has decreed free healthcare in the 3 health
zones most affected by the epidemic, namely Mabalako, Oicha, and Beni
[North Kivu]. Since Mon 20 Aug 2018, free care is effective in the 7
public health centers of Mabalako and will be effective in other
affected areas in the coming days.

Immunization activities continue at the three sites of Mabalako, Beni,
and Mandima. Since vaccination began on 8 Aug 2018, 1273 people have
been vaccinated , including 697 in Mabalako, 367 in Beni, and 209 in

A new Ebola Treatment Center (ETC) will be built in Makeke, Mandima
Health Zone, in Ituri province. During the last visit of the Minister
of Health to Mangina, the epicenter of the epidemic, it was found that
the 50-bed ETC installed by Médecins Sans Frontières (MSF) was
filling up rapidly and could no longer accommodate additional patients
given the rapid increase in confirmed and suspicious cases to be
supported. Thus, the coordination made the decision to install a 2nd
ETC in this area. Due to the lack of space in Mangina and the demands
of the population, this new ETC will be built in Makeke, a neighboring
area of Mangina, which also reported confirmed cases.

Response plan
The response plan submitted by the Ministry of Health has been
approved and all funds necessary for its implementation have been
lifted. The Ministry of Health thanks the partners for their
collaboration and contribution to the response.

Communicated by:
ProMED-mail Rapporteur Mary Marshall

[The number of cases is increasing steadily, especially in Mabalako,
as are the deaths, which is a disturbing trend. More ETCs are being
built in anticipation of the ever increasing number of patients
needing care. Offering free health care is an important step as
individuals will be more likely to come to the clinics when they are
sick. - Mod.LK

Important questions raised by Crofsblog
"Out of today's 5 new deaths, how many were in the community and how
many in the local ETC? How many of the cases in this outbreak are
family clusters? Are "red zone" nurses still able to phone in to
report on their local cases? And if MSF's 50-bed hospital is filling
up, how big will the new ETC be, and how quickly can it be up and
running?" - Rapp.MM

HealthMap/ProMED-mail map:
North Kivu, Congo: <http://healthmap.org/promed/p/29837>]

[2] Experimental anti-viral
- Mon 20 Aug 2018. DRC: experimental Ebola treatment 'successful-
[africanews, Reuters report [edited]

The Democratic Republic of Congo's National Institute for Biomedical
Research (INRB) has said a drug used for the 1st time on Ebola
patients, the mAb114, is working well in North Kivu. It said it
expects some patients to leave hospital on Tue 21 Aug 2018.

Professor Jean-Jacques Muyembe, the INRB's director-general said 10
Ebola patients had received mAb114 in Beni and that they are waiting
for its US manufacturers to deliver more doses this week.

"Until now 10 people have already received this treatment (mAb114) via
infusion, it's an hour of treatment, one injection and until now all
10 are getting better and I think Mon or Tue [20-21 Aug 2018] the 1st
case will leave the hospital," said Muyembe.

Muyembe said another 5 treatments that have been approved by the WHO
including Zmapp, Regeneron, Remdesvir, and Favipiravir should also be

The patients receiving mAb114 have been closely monitored and no side
effects have yet been identified although he added it was too early to

The mAb114 treatment was developed in the United States from a blood
sample of an Ebola survivor in Kikwit, DRC, in 1995 and was 100
percent effective when tested on monkeys.

Muyembe said if the treatment was fully effective the fight to control
the spread of Ebola in North Kivu could move from containment to

"This epidemic (in north Kivu) is not like the epidemic in Equateur
that we have known already. This epidemic will bring with it a lot of
surprises: the number of cases is going up and the number of infected
zones is increasing so it will take a long time to control this
epidemic and for the anti-virals which the companies will provide us,
they are ready to increase the doses," said Muyembe.

There have been renewed campaigns to raise awareness and inform the
public on how to protect themselves.

Communicated by:
ProMED-mail Rapporteur Mary Marshall

[The apparent success of mAb114 is very exciting, but it may be a
little early to label it a cure, even if all continues to go well. It
is a concern that conditions may often be too basic in many locations
to use mAb114 on a regular basis, since it has to be delivered in an
infusion, as do some of the other experimental therapies. Furthermore,
it will always take a multi-pronged approach to control Ebola
transmission including cessation of hunting bushmeat, adoption of
personal protective measures, safe burials, vaccination, and
anti-virals in concert to meet the challenges of this devastating
virus. - Mod.LK]

[3] Research
- bioRxiv
[ref: Wec AZ, Bornholdt ZA, He Shihua, et al. Human antibody cocktail
deploys multiple functions to confer pan-ebolavirus protection.
bioRxiv 395525;
Abstract. During the unprecedented 2013-2016 Ebola virus disease (EVD)
epidemic in Western Africa and in its aftermath, the passive
administration of monoclonal antibodies (mAbs) emerged as a promising
treatment approach. However, all antibody-based therapeutics currently
in advanced development are specific for a single member of the
_Ebolavirus_ genus, Ebola virus (EBOV), and ineffective against
divergent outbreak-causing ebolaviruses, including Bundibugyo virus
(BDBV) and Sudan virus (SUDV). Here we advance MBP134, a cocktail of 2
broadly neutralizing human mAbs targeting the filovirus surface
glycoprotein, GP, as a candidate pan-ebolavirus therapeutic. One
component of this cocktail is a pan-ebolavirus neutralizing mAb,
ADI-15878, isolated from a human EVD survivor. The second, ADI-23774,
was derived by affinity maturation of a human mAb via yeast display to
enhance its potency against SUDV. MBP134 afforded exceptionally potent
pan-ebolavirus neutralization in vitro and demonstrated greater
protective efficacy than ADI-15878 alone in the guinea pig model of
lethal EBOV challenge. A second-generation cocktail, MBP134-AF,
engineered to effectively harness natural killer (NK) cells afforded
additional, unprecedented improvements in protective efficacy against
EBOV and SUDV in guinea pigs relative to both its precursor and to any
mAbs or mAb cocktails tested previously. MBP134 AF is a best-in-class
mAb cocktail suitable for evaluation as a pan-ebolavirus therapeutic
in nonhuman primates.

Communicated by:
ProMED-mail Rapporteur Mary Marshall

[See Also:
Ebola update (72): Congo DR (NK) cases, response, research
Ebola update (71): Congo DR (NK) cases, response, bats
Ebola update (70): Congo DR (NK) cases, recommendations, war, comment
Ebola update (69): Congo DR (NK,IT) cases, Uganda NOT, WHO response
Ebola update (68): Congo DR (NK) WHO, Uganda cases, concerns,
challenges http://promedmail.org/post/20180815.5966397
Ebola update (67): Congo DR (NK) cases, response, issues, research
Ebola update (66): Congo DR (NK) cases, response
Ebola update (65): Congo DR (NK) cases, vaccines
Ebola update (64): Congo DR (NK) cases, security, genome
Ebola update (63): Congo DR (NK) cases, vaccine, security, burial,
genome http://promedmail.org/post/20180809.5957277
Ebola update (62): Congo DR (NK) WHO, response, genetics
Ebola update (61): Congo DR (NK) WHO, cases, response
Ebola update (60): DR Congo (NK) case update, response, risk
Ebola update (59): Congo DR (NK) case update, risk, response,
treatment http://promedmail.org/post/20180804.5946851
Ebola update (58): Congo DR (NK) outbreak, Ebola Zaire confirmed
Ebola update (57): Congo DR (NK):
Ebola update (56): northeast Congo DR, Ebola-like cases, US negative,
RFI http://promedmail.org/post/20180730.5936610
Ebola update (55): Sierra Leone Ebola virus variant, Congo DR cases,
WHO http://promedmail.org/post/20180727.5931686
Ebola update (54): Congo DR, cases, therapeutics
Ebola update (53): Congo DR, cases, surveillance, action
Ebola update (52): Congo DR, cases, health workers, W Africa survivor
problems http://promedmail.org/post/20180713.5902694
Ebola update (51): Congo DR, cases, response
Ebola update (50): Congo DR, Japanese response, CIDRAP, WHO, survey
Ebola update (49): Congo DR, suspect deaths comment
Ebola update (48): Congo DR, MSF, susp. deaths, RFI
Ebola update (47): DR Congo, epidemiology, response, Libya RFI
Ebola update (46): Congo DR, cases
Ebola update (45): Congo DR, cases, outbreak, MSF
Ebola update (44): Congo DR, cases, research, course
Ebola update (43): Congo DR, cases, vaccine, persistence, lessons
Ebola update (42): Congo DR, cases, vaccine
Ebola update (41): Congo DR, cases, WHO, contacts
Ebola update (40): Congo DR, cases, WHO, vaccine, treatment,
preparedness http://promedmail.org/post/20180622.5869267
Ebola update (39): Congo DR, cases, WHO, response, facilities,
treatment, research http://promedmail.org/post/20180620.5865023
Ebola update (38): DR Congo, cases, WHO, Oxfam
Ebola update (37): Congo DR, cases, response
Ebola update (36): Congo DR, cases, threat, assistance
Ebola update (35): Congo DR, cases, response, WHO
Ebola update (34): Congo DR, cases, response, WHO
Ebola update (33): Congo DR, cases, response, WHO, diagnosis
Ebola update (32): Congo DR, cases, preparation, research
Ebola update (31): Congo DR, cases, response, WHO
Ebola update (30): Congo DR, cases, WHO, action
Ebola update (29): Congo DR, cases, MSF, antivirals
Ebola update (28): Congo DR, cases, WHO, response, treatment, funding
Ebola update (27): Congo DR, cases, travel screening, children
Ebola update (26): Congo DR, border controls, bat reservoir
Ebola update (25): Congo DR, case update, intl. travel screening
Ebola update (24): Congo DR, case update, African aid response
Ebola update (23): Congo DR, cases, vacc. campaign targets, vaccine
development http://promedmail.org/post/20180601.5834040
Ebola update (22): Congo DR, cases, cures, domestic and international
travel http://promedmail.org/post/20180531.5831747
Ebola update (21): Congo DR, update, WHO, vaccination, therapeutics
Ebola update (20): Congo DR, case update, lessons, logistics,
financing, flights http://promedmail.org/post/20180529.5824985
Ebola update (19): Congo DR, case update
Ebola update (18): cases, Uganda NOT, Congo DR vaccination campaign
Ebola update (17): case update, public fears, government responses
Ebola update (16): cases, Congo DR cultural factors, vaccine impl.,
case terminology http://promedmail.org/post/20180525.5817907
Ebola update (15): case update, quarantine breaches, border controls,
vaccine http://promedmail.org/post/20180524.5816349
Ebola update (14): case update, response, prediction, maps
Ebola update (13): case update, prevention
Ebola update (12): update, USA, response
Ebola update (11): WHO, vaccination, response
Ebola update (10): urban case Congo DR, response, support
Ebola update (09): update, alerts, prevention
Ebola update (08): summary, emergency plan, vaccine, roads
Ebola update (07): Congo DR, nurse, Uganda susp, WHO, border, vaccine
Ebola update (06): Congo DR, susp, RFI, vulnerability, response,
control http://promedmail.org/post/20180512.5794300
Ebola update (05): Congo DR, outbreak update, vaccine, preparedness,
research http://promedmail.org/post/20180511.5792856
Ebola update (04): Nigeria, Kenya, Congo DR (ET), WHO
Ebola update (03): Congo DR (ET), WHO
Ebola update (02): Congo DR (ET)
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
Donate to ProMED-mail. Details available at:
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to
an individual moderator). If you do not give your full name
name and affiliation, it may not be posted. You may unsub-
scribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php


Post a Comment